Theravance Biopharma (TBPH) EBT Margin (2013 - 2026)
Theravance Biopharma's (TBPH) quarterly EBT Margin came in at 36.56% in Q1 2026, up 5532.0% year-on-year from 0.65% in Q1 2025, and down 132.13% on a QoQ basis from 113.77% in Q4 2025.
Theravance Biopharma (TBPH) EBT Margin (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has 14 years of EBT Margin data on file, last reported at 36.56% in Q1 2026.
- On a quarterly basis, EBT Margin rose 5532.0% year-over-year to 36.56% in Q1 2026; TTM through Mar 2026 was 105.72%, a 17980.0% increase from a year earlier, with the FY2025 full-year figure at 1445.2%, up 151450.0% from the prior year.
- EBT Margin for Q1 2026 stood at 36.56%, down from 113.77% in the prior quarter.
- Over the last five years, EBT Margin for TBPH reached as high as 279.47% in Q2 2025 and fell as low as 301.11% in Q1 2022.
- Historically, EBT Margin has averaged 68.51% across 5 years, with a median of 71.72% in 2024.
- On a YoY basis, EBT Margin climbed as much as 38623 bps in 2025 and fell as far as 2015 bps in 2025.
- Year by year, EBT Margin stood at 97.34% in 2022, then surged by 71 bps to 28.56% in 2023, then sank by 67 bps to 47.66% in 2024, then surged by 339 bps to 113.77% in 2025, then slumped by 132 bps to 36.56% in 2026.
- Per Business Quant data, the three most recent EBT Margin figures were 36.56% in Q1 2026, 113.77% in Q4 2025, and 14.45% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Theravance Biopharma | 864.56 Mn | 469.90 Mn | - | -36.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36.56% |
| Dec 31, 2025 | 113.77% |
| Sep 30, 2025 | -14.45% |
| Jun 30, 2025 | 279.47% |
| Mar 31, 2025 | -91.88% |
| Dec 31, 2024 | -47.66% |
| Sep 30, 2024 | -59.59% |
| Jun 30, 2024 | -106.77% |
| Mar 31, 2024 | -71.72% |
| Dec 31, 2023 | -28.56% |
| Sep 30, 2023 | -48.32% |
| Jun 30, 2023 | -103.19% |
| Mar 31, 2023 | -215.83% |
| Dec 31, 2022 | -97.34% |
| Sep 30, 2022 | -128.69% |
| Jun 30, 2022 | -206.32% |
| Mar 31, 2022 | -301.11% |
| Dec 31, 2021 | -387.84% |
| Sep 30, 2021 | -423.81% |
| Jun 30, 2021 | -407.50% |